Khiron Life Sciences Corp. (KHRWF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Khiron Life Sciences Corp. (KHRWF) trades at $0.015. Khiron Life Sciences Corp. is an integrated medical cannabis company operating in Latin America and Europe. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for KHRWF: KHRWF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KHRWF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
KHRWF: 2/3 scored disciplines lean bearish. Dominant signal: Jim Simons bullish.
How is this calculated? →Khiron Life Sciences Corp. (KHRWF) Healthcare & Pipeline Overview
Khiron Life Sciences Corp. is a vertically integrated medical cannabis company focused on Latin America and Europe, cultivating, producing, and distributing medical cannabis and CBD products. The company operates health centers and develops cosmeceuticals, differentiating itself through a comprehensive approach to cannabis-based healthcare solutions.
What Is the Investment Thesis for KHRWF?
Khiron Life Sciences Corp. presents a speculative investment thesis centered on the growth of the medical cannabis market in Latin America and Europe. Key value drivers include the expansion of its Zerenia clinic network, increased sales of medical cannabis products, and the growth of its Kuida cosmeceutical brand. The company's integrated business model, encompassing cultivation, production, distribution, and clinic operations, offers potential for margin expansion. However, the company's negative profit margin of -258.9% indicates significant challenges to profitability. Upcoming regulatory changes in key markets and successful product launches could serve as catalysts. Potential risks include intense competition, regulatory hurdles, and the company's ability to secure additional financing.
Based on FMP financials and quantitative analysis
KHRWF Key Highlights
Khiron Life Sciences Corp. operates in the rapidly growing medical cannabis market in Latin America and Europe.
- The company's integrated business model spans cultivation, production, distribution, and clinic operations.
- Khiron's network of health centers and satellite clinics under the ILANS and Zerenia brands provides a direct channel to patients.
- The company's Kuida brand offers CBD-based cosmeceutical products targeting the skincare and personal care markets.
- Khiron's negative profit margin of -258.9% indicates significant challenges to profitability.
Who Are KHRWF's Competitors?
KHRWF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ZTS Zoetis Inc. | $75.44 | -1.62% | $31.6B | 85 |
| ITCI ITCI | $131.87 | +0.00% | $14.1B | 63 |
| ESALF Eisai Co., Ltd. | $29.90 | +0.00% | $8.44B | 61 |
| LNTH Lantheus Holdings, Inc. | $100.24 | -0.24% | $6.53B | 88 |
| AMRX Amneal Pharmaceuticals, Inc. | $17.90 | -1.16% | $5.72B | 65 |
| CAMRF Camurus AB (publ) | $64.00 | +0.00% | $3.81B | 63 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
| AVDL Avadel Pharmaceuticals plc | $21.64 | +0.00% | $2.12B | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KHRWF's Key Strengths?
Integrated business model.
- Focus on Latin American and European markets.
- Established network of health centers and satellite clinics.
- CBD-based cosmeceutical product line.
What Are KHRWF's Weaknesses?
Negative profit margin.
- Limited financial resources.
- Dependence on regulatory approvals.
- Intense competition.
What Could Drive KHRWF Stock Higher?
Regulatory approvals for medical cannabis products in new markets.
- Expansion of the Zerenia clinic network.
- Launch of new medical cannabis formulations.
- Increasing acceptance of medical cannabis in Latin America and Europe.
What Are the Key Risks for KHRWF?
Negative return on equity (-68.6%) — the business is not currently generating profit on shareholder capital.
- Regulatory changes and uncertainty.
- Competition from established pharmaceutical companies.
- Fluctuations in cannabis prices.
- Negative profit margin and limited financial resources.
- Shell Risk Detected.
What Are the Growth Opportunities for KHRWF?
- Expansion of Zerenia Clinic Network: Khiron has the opportunity to expand its network of Zerenia clinics across Latin America and Europe. These clinics provide a direct channel to patients and allow the company to offer specialized medical consultations and treatments utilizing cannabis-based therapies. The expansion of the clinic network could significantly increase patient access and drive revenue growth. The market size for medical cannabis clinics is projected to grow as acceptance of cannabis-based therapies increases.
- Increased Sales of Medical Cannabis Products: Khiron can increase sales of its medical cannabis products by expanding its distribution network and launching new formulations. The company's focus on tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis allows it to target a wide range of medical conditions. The market for medical cannabis products is growing rapidly, driven by increasing legalization and acceptance of cannabis-based therapies. Successful product launches and strategic partnerships could accelerate sales growth.
- Growth of Kuida Cosmeceutical Brand: Khiron has the opportunity to grow its Kuida cosmeceutical brand by expanding its product line and distribution channels. The Kuida brand offers CBD-based skincare and personal care products targeting the wellness market. The market for CBD-based cosmeceuticals is growing rapidly, driven by increasing consumer awareness of the potential benefits of CBD. Successful product launches and strategic partnerships could accelerate brand growth.
- Strategic Partnerships and Acquisitions: Khiron can pursue strategic partnerships and acquisitions to expand its market reach and product offerings. Partnerships with pharmaceutical companies, wellness brands, and healthcare providers could provide access to new markets and distribution channels. Acquisitions of complementary businesses could expand the company's product portfolio and strengthen its competitive position. Strategic partnerships and acquisitions could accelerate the company's growth and enhance its long-term value.
- Regulatory Approvals and Market Access: Khiron's growth is heavily dependent on securing regulatory approvals and gaining market access in key markets. Obtaining licenses to cultivate, produce, distribute, and export medical cannabis is essential for the company's operations. Navigating the complex regulatory landscape in Latin America and Europe requires expertise and resources. Successful regulatory approvals and market access could significantly expand the company's addressable market and drive revenue growth.
What Are KHRWF's Competitive Advantages?
- Integrated business model spanning cultivation, production, distribution, and clinic operations.
- Brand recognition and reputation in the Latin American and European markets.
- Proprietary formulations and intellectual property related to medical cannabis products and cosmeceuticals.
What Does KHRWF Do?
Khiron Life Sciences Corp., established in 2012 and headquartered in Vancouver, Canada, operates as an integrated medical cannabis company with a focus on Latin America and Europe. The company's business is structured around three key segments: Health Services, Medical Cannabis Products, and Wellbeing Products. Khiron cultivates, produces, distributes, and exports tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. Khiron's Health Services segment encompasses a network of health centers and satellite clinics operating under the ILANS and Zerenia brands. These clinics provide specialized medical consultations and treatments utilizing cannabis-based therapies. The Medical Cannabis Products segment focuses on the development and distribution of a range of medical cannabis formulations. The Wellbeing Products segment centers on the development of CBD-based cosmeceutical products under the Kuida brand, targeting the skincare and personal care markets. Khiron also operates a Zerenia clinic in Medellin, Colombia, and Peru, expanding its reach in the Latin American market. The company aims to establish itself as a leading provider of cannabis-based health and wellness solutions in its target markets.
What Products and Services Does KHRWF Offer?
- Cultivates medical cannabis.
- Produces medical cannabis products containing THC and CBD.
- Distributes medical cannabis products to patients and healthcare providers.
- Exports medical cannabis products to international markets.
- Operates a network of health centers and satellite clinics under the ILANS and Zerenia brands.
- Develops CBD-based cosmeceutical products under the Kuida brand name.
How Does KHRWF Make Money?
- Khiron generates revenue from the sale of medical cannabis products.
- The company generates revenue from health services provided at its clinics.
- Khiron generates revenue from the sale of CBD-based cosmeceutical products.
What Industry Does KHRWF Operate In?
Khiron Life Sciences Corp. operates within the burgeoning medical cannabis industry, which is experiencing rapid growth due to increasing legalization and acceptance of cannabis-based therapies. Khiron competes with other cannabis companies, pharmaceutical companies, and wellness brands. The company's focus on Latin America and Europe differentiates it from competitors primarily focused on North America. The regulatory landscape and market dynamics vary significantly across different countries, presenting both opportunities and challenges.
Who Are KHRWF's Key Customers?
- Patients seeking medical cannabis treatments.
- Healthcare providers prescribing medical cannabis.
- Consumers purchasing CBD-based cosmeceutical products.
Company Profile
Khiron Life Sciences Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. The company is led by CEO Alvaro Francisco Torres.
Key Financial Metrics
Return on equity for Khiron Life Sciences Corp. stands at -68.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -78.4%, showing how much profit it generates from its asset base. A current ratio of 3.08 indicates the company holds enough short-term assets to cover its near-term obligations.
KHRWF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Integrated business model.
- Focus on Latin American and European markets.
- Established network of health centers and satellite clinics.
- CBD-based cosmeceutical product line.
Bear Case
- Negative profit margin.
- Limited financial resources.
- Dependence on regulatory approvals.
- Intense competition.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
KHRWF Latest News
No recent news available for KHRWF.
KHRWF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KHRWF.
Price Targets
Wall Street price target analysis for KHRWF.
KHRWF MoonshotScore
What does this score mean?
The MoonshotScore rates KHRWF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Alvaro Francisco Torres
CEO
Alvaro Francisco Torres serves as the Chief Executive Officer of Khiron Life Sciences Corp. His background includes experience in the pharmaceutical and healthcare industries. He has held various leadership positions in companies focused on Latin American markets. His expertise lies in strategic planning, business development, and operations management. He is responsible for guiding Khiron's overall strategy and execution.
Track Record: Under Alvaro Francisco Torres' leadership, Khiron Life Sciences Corp. has focused on expanding its operations in Latin America and Europe. Key milestones include the establishment of the Zerenia clinic network and the launch of the Kuida cosmeceutical brand. The company has also focused on securing regulatory approvals for its medical cannabis products in various markets.
KHRWF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Khiron Life Sciences Corp. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies on the OTC Other tier may have limited financial disclosure and may not be subject to the same regulatory requirements as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Lower liquidity and higher price volatility.
- Potential for fraud or manipulation.
- Limited regulatory oversight.
- Shell Risk Detected.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Monitor the company's news and press releases for any red flags.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Operations in multiple countries (Latin America and Europe).
- Presence of health centers and satellite clinics.
- Development of CBD-based cosmeceutical products.
- Focus on the medical cannabis market.
KHRWF Healthcare Stock FAQ
What does Khiron Life Sciences Corp. do?
Khiron Life Sciences Corp. operates as an integrated medical cannabis company in Latin America and Europe. The company cultivates, produces, distributes, and exports medical cannabis products containing THC and CBD. Khiron also operates a network of health centers and satellite clinics under the ILANS and Zerenia brands, providing specialized medical consultations and treatments utilizing cannabis-based therapies.
What are the main risks for KHRWF?
Khiron Life Sciences Corp. faces several risks, including regulatory uncertainty, competition, and financial challenges. Changes in regulations regarding medical cannabis could impact the company's ability to operate and expand its business. Competition from established pharmaceutical companies and other cannabis companies could put pressure on prices and market share.
How does Khiron Life Sciences Corp. navigate regulatory approval processes?
Khiron Life Sciences Corp. navigates regulatory approval processes by engaging with regulatory bodies in each target market, submitting required documentation, and adhering to local regulations. The company focuses on building relationships with key stakeholders and demonstrating compliance with quality standards. Securing regulatory approvals is essential for Khiron to cultivate, produce, distribute, and export medical cannabis products.
What revenue streams does Khiron Life Sciences Corp. have in healthcare?
Khiron Life Sciences Corp. generates revenue from several healthcare-related streams. These include the sale of medical cannabis products, revenue from health services provided at its Zerenia clinics, and sales of CBD-based cosmeceutical products. The medical cannabis products target a range of medical conditions, while the Zerenia clinics offer specialized medical consultations and treatments utilizing cannabis-based therapies.
What are the key factors to evaluate for KHRWF?
Evaluate KHRWF on fundamentals, analyst consensus, and risk factors. Khiron Life Sciences Corp. presents a speculative investment thesis centered on the growth of the medical cannabis market in Latin America and Europe. Not financial advice.
How frequently does KHRWF data refresh on this page?
KHRWF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven KHRWF's recent stock price performance?
Khiron Life Sciences Corp. (KHRWF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated business model. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KHRWF overvalued or undervalued right now?
Khiron Life Sciences Corp. (KHRWF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- AI analysis pending may limit the completeness of the analysis.